

PHARMACEUTICAL ECONOMICS AND POLICY

Second Edition

Stuart O. Schweitzer

OXFORD
UNIVERSITY PRESS
2007

Contents

Introduction	3
<i>The Supply of Pharmaceuticals</i>	5
<i>The Demand for Pharmaceuticals</i>	7
<i>Pharmaceutical Prices</i>	8
<i>The Multinational Pharmaceutical Industry</i>	11
<i>International Price Comparisons</i>	12
<i>Timing of Pharmaceutical Approvals</i>	12
<i>Government Intervention in the Pharmaceutical Sector</i>	13

Part I. The Industry

1	The Pharmaceutical Industry	21
	<i>Pharmaceutical Research and Development</i>	22
	<i>The Competitive Structure of the Pharmaceutical Industry</i>	23
	<i>Pharmaceutical Research and Development and Prices</i>	27
	<i>The Pharmaceutical Research Process</i>	29
	<i>Product Liability</i>	38
	<i>Conclusions</i>	40
2	The Biotechnology Industry	44
	<i>Background</i>	44
	<i>Product Development in the Biotechnology Industry</i>	47
	<i>The Natural History of Biotechnology Firms</i>	48
	<i>Case Studies of Alliances</i>	53
	<i>Regulation</i>	55
	<i>Case Studies of Biotechnology Firm Growth</i>	57
	<i>Conclusions</i>	60

xii Contents

3	Other Firms in the Pharmaceutical Industry	63
	<i>Generic Drugs and Their Manufacturers</i>	63
	<i>Outsourcing Firms</i>	68
	<i>Conclusions</i>	78
4	Marketing Pharmaceuticals	82
	<i>Size of Marketing Effort</i>	85
	<i>Does It Work?</i>	85
	<i>Types of Promotion</i>	87
	<i>Disguising Marketing as Research</i>	93
	<i>Marketing in an Era of Managed Care</i>	94
	<i>Pharmacy Benefit Managers</i>	95
	<i>Direct-to-Consumer Advertising</i>	97
	<i>Over-the-Counter Drugs</i>	100
	<i>Joint Marketing</i>	103
	<i>Disease Management</i>	103
	<i>Roles of the U.S. Food and Drug Administration in Marketing</i>	104
	<i>False and Misleading Claims</i>	105

Part II. The Consumer

5	The Demand for Pharmaceuticals	115
	<i>How Is Demand Determined?</i>	116
	<i>The Changing Structure of the Pharmaceutical Market</i>	117
	<i>Conclusions</i>	131

Part III. The Market

6	Pharmaceutical Prices	137
	<i>The Problem of Pharmaceutical Prices</i>	138
	<i>Pharmaceutical Prices over Time</i>	139
	<i>Measuring Drug Prices</i>	141
	<i>How Are Drug Prices Determined? .</i>	143
	<i>Cost Structure of Pharmaceutical Firms</i>	144
	<i>Is the Pharmaceutical Industry Monopolistic?</i>	149
	<i>How Drug Quality Influences Price</i>	153
7	The Worldwide Market for Pharmaceuticals	157
	<i>Geographic Patterns of Pharmaceutical Production and Sales</i>	158
	<i>Pharmaceutical Research and Development: An International View</i>	159
	<i>Does Government Drug Price Setting Influence R&D?</i>	166
	<i>Worldwide Manufacturing and Sales</i>	167
	<i>Access to Appropriate Drugs in Developing Countries</i>	170
	<i>Effect of the World Trade Organization Treaty</i>	173
8	Pricing Pharmaceuticals in a World Environment	177
	<i>Why Do Drug Prices Vary Across Country?</i>	178
	<i>Comparisons of International Drug Prices</i>	180
	<i>How Do We Measure Drug Prices across Countries?</i>	184

	<i>Why Drug Price Differences Persist</i>	186
	<i>Policy Implications</i>	186
9	The Timing of Drug Approvals in the United States and Abroad	191
	<i>The Timing of Pharmaceutical Approvals and Health Policy</i>	192
	<i>The Drug Approval Process in the United States</i>	193
	<i>Recent Initiatives to Expedite Drug Approvals</i>	198
	<i>Is There a U.S. Drug Lag?</i>	199
Part IV. Intervention in the Pharmaceutical Market: Public and Private		
10	Pharmaceutical Regulation and Cost Containment by the Public Sector	209
	<i>Evolution of the U.S. Food and Drug Administration</i>	210
	<i>Medicaid</i>	211
	<i>State Cost-Containment Efforts</i>	213
	<i>Medicare</i>	214
11	Regulation by the Private Sector	222
	<i>Cost-Containment Mechanisms</i>	222
	<i>Cost Containment in Managed Care</i>	230
12	Pharmaceutical Regulation in Europe	238
	<i>The Pharmaceutical Industry in Europe</i>	238
	<i>History of Regulation in Europe</i>	239
	<i>Move Toward a Single Market</i>	240
	<i>Structure and Role of the European Medicines Evaluation Agency</i>	240
	<i>Drug Review under the European Medicines Evaluation Agency</i>	241
	<i>Current Regulatory Structure</i>	242
	<i>The Centralized Procedure for Marketing Authorization</i>	243
	<i>The Mutual-Recognition Procedure</i>	245
	<i>Performance of Europe's Centralized Drug Approval</i>	246
	<i>Rules on Labeling of Medicinal Products</i>	247
	<i>Advertising Regulations</i>	248
	<i>Pharmacovigilance</i>	248
	<i>Generic Drugs</i>	249
13	Patent Protection	252
	<i>Patent Law</i>	253
	<i>Patentability and Patent Categories</i>	254
	<i>How Are Patents Obtained?</i>	255
	<i>What Protection Does a Patent Confer?</i>	256
	<i>Duration of Patent Protection</i>	256
	<i>Infringement of Patents</i>	258
	<i>International Patent Treaties</i>	258
	<i>Patent Procedures under International Conventions</i>	260
	<i>Shortcomings of the Patent System</i>	260
	<i>Patents and Societal Choice</i>	261
	<i>Social Benefits of the Patent System</i>	261

xiv Contents

14	Evaluating New Drugs	263
	<i>Optimizing Production of Health</i>	263
	<i>Cost-Benefit Analysis</i>	266
	<i>Cost-Effectiveness Analysis</i>	270
	<i>Cost-Utility Analysis</i>	272
	<i>Policy Applications</i>	274
	<i>Interpretation and Misinterpretation of Cost-Effectiveness Studies</i>	277
15	Complementary and Alternative Medicines	280
	<i>Who Uses Complementary and Alternative Medicines?</i>	282
	<i>Manufacturers and Distributors of Complementary and Alternative Medicines</i>	282
	<i>Dietary Supplements</i>	283
	<i>Food Additives</i>	293
	<i>Medical Foods</i>	296
	<i>Concluding Remarks on Complementary and Alternative Medicines</i>	300
16	Pharmaceuticals and Health Policy: A Look Ahead	304
	<i>Structure of the Pharmaceutical Industry</i>	304
	<i>Health System Reform</i>	306
	<i>Drug Prices</i>	308
	<i>Drug Imports</i>	308
	<i>Patent Protection</i>	309
	<i>Drug Approvals</i>	310
	<i>Managed Care and Restricted Access to Pharmaceuticals</i>	311
	<i>The U.S. Food and Drug Administration</i>	313
	<i>Genetically Targeted Drugs</i>	314
	<i>Conclusions</i>	315
	Index	317